Early Actions of Anti–Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels
Open Access
- 20 July 2017
- journal article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 187 (10), 2337-2347
- https://doi.org/10.1016/j.ajpath.2017.06.010
Abstract
No abstract availableKeywords
Funding Information
- NIH (P01 CA-92644, 5 R01 CA196996-02)
This publication has 48 references indexed in Scilit:
- Dynamic responses of endothelial cells to changes in blood flow during vascular remodeling of the mouse yolk sacDevelopment, 2013
- The vascular-disrupting agent, combretastatin-A4-phosphate, enhances neurogenic vasoconstriction in rat small arteriesEuropean Journal of Pharmacology, 2012
- Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in ratsVascular Pharmacology, 2009
- Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancerNature Reviews Cancer, 2008
- How Tumors Make Bad Blood Vessels and StromaThe American Journal of Pathology, 2003
- A Novel Concept of Glomeruloid Body Formation in Experimental Cerebral MetastasesJournal of Neuropathology and Experimental Neurology, 2003
- Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers.2002
- VEGF-Trap: A VEGF blocker with potent antitumor effectsProceedings of the National Academy of Sciences of the United States of America, 2002
- Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine.1997
- Tumoral vascularity as a prognostic factor in cancer.1996